Ovarian Cancer Clinical Trial
Official title:
Stress, Immunity & Cervical Cancer: Biobehavioral Outcomes of a Randomized Trial
The purpose of the study is to:
1. Test the efficacy of psychosocial telephone counseling (PTC) for cervical cancer
survivors, compared to usual care.
2. Evaluate the longitudinal immune and neuroendocrine parameters in cervical cancer
patients who have received PTC, compared to usual care.
3. Examine the longitudinal relationship between PTC associated modulations of quality of
life (QOL) measures and biologic parameters (immune and neuroendocrine).
The incidence and mortality rates for invasive cervical cancer in minority, low-income, and
less educated women exceeds that for white, higher income, and better educated women. In
southern California the incidence and mortality rates for cervical cancer are nearly twice
that of non-Latina white women. Our preliminary work supports and extends the extant
literature, noting that quality of life can be significantly disrupted among cervical cancer
survivors, with qualitative differences in how Latina women experience cancer survivorship.
However, there is a paucity of literature on interventions designed to assist cervical cancer
survivors manage illness-specific stress and improve health behaviors. Our current NIH-funded
work suggests that a six session psychosocial telephone counseling (PTC) intervention can
improve QOL and decrease psychological distress, with accompanying intervention-induced
neuroendocrine and immune parameter modulations which may be related to disease endpoints. In
primary support of these significant biobehavioral findings, the project herein proposes to
accomplish the following Specific Aims:
1. Test the efficacy of PTC for cervical cancer survivors, compared to usual care.
2. Evaluate the longitudinal immune and neuroendocrine parameters in cervical cancer
patients who have received PTC, compared to usual care.
3. Examine the longitudinal relationship between PTC associated modulations of QOL measures
and biologic parameters (immune and neuroendocrine).
To achieve these aims the investigators will randomize patients ascertained through the two
SEER cancer registries to PTC (N=125) or usual care (N=125), stratifying on English or
Spanish language preference. Assessments will occur at baseline (9-20 months post diagnosis),
and three and nine months post enrollment/baseline. Assessments will include evaluation of
QOL (overall QOL, psychological distress, coping, social support, sexual functioning), health
behaviors, neuroendocrine parameters dehydroepiandrosterone sulfate, growth hormone [DHEA-S,
cortisol, GH] and immunologic parameters (natural killers [NK] cell activity, IL-5,
interferon, human papillomavirus (HPV) E6/E7 peptides, IL-15, IL 10). This project has
significant public health relevance for an important unstudied cancer survivor population,
many of whom are poor and underserved. If effective, an intervention which could improve
quality of life (QOL) and health behaviors, and enhance neuroendocrine and immune responses
for women with cervical cancer could have significant implications toward disease recurrence
or survival.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |